Search Results for "Top 10 Neuroscience Projects To Watch 2013 14"

00:35 EDT 1st April 2015 | BioPortfolio

Matching Channels

Mesenchymal Epithelial Transition factor c MET

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF...


AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and em...

Staphylococcal aureus infections

Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently...

Merck and Co

Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the ...


Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in ...

Matching News

Where will big neuroscience take us?

(The Kavli Foundation) The US, Europe and Asia have launched big brain research projects. What impact will they have? Scientists integral to three projects share their insights ahead of a special sess...

Cynapsus’ APL-130277 one of “Top Ten Neurology Projects to Watch”

Cynapsus Therapeutics’ (OTCQX:CYNAF; TSX-V:CTH) APL-130277 drug candidate for Parkinson’s disease has been recognized as one of the “Top Ten Neurology Projects to Watch” by a joint sel...

Reversing Blindness and Eliminating Deafness

New grants for five research projects awarded by the Bertarelli Program in Translational Neuroscience and Neuroengineering The Bertarelli Program in Translational Neuroscience and Neuroengineering, a ...

Neuroscience Treatments To Watch

Breakthroughs in genetics and sheer stubbornness on the part of drug developers could soon lead to new drugs for intractable brain diseases, including:

Stocks To Watch If You're Betting on the Brain

Want to invest in neo-neuroscience? Here's our red-yellow-green take on eight stocks attracting investor attention.

Stocks To Watch If You’re Betting on the Brain

Want to invest in neo-neuroscience? Here's our red-yellow-green take on eight stocks attracting investor attention.

Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch

CRANBURY, N.J., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announc...

Blackrock Microsystems initiates two industry partnerships for neuroscience research

Blackrock Microsystems, the industry leader in neuroscience research equipment, today announced partnerships with two neuroscience research firms -- Germany-based PhenoSys and Israel-based NAN Instr...

Matching PubMed Articles

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement